Bone cancer systemic therapy agents...Pembrolizumab for TMB-H...TMB-H for patients with unresectable or metastatic tumors who have progressed following prior treatment and who have no satisfactory alternative treatment options.

KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated:...for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.